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Sir,
Small bowel adenocarcinoma (SBA) is a rare and aggressive tumour.
SBA in the United States increased from 5.7 cases per million in 1973 to
7.3 cases per million in 2004 (Surveillance Epidemiology and End
Results (SEER), 1973–2004 database; Jemal et al (2009). Surgery is the
mainstay of treatment, even if chemotherapy in advanced disease has
been associated with an increased survival. The most effective agents
include 5-FU, irinotecan, platinum agents and gemcitabine (Fishman
et al, 2006; Speranza et al, 2010). The molecular characterisation of this
cancer could help to improve prognosis. Specifically, the frequency of
KRAS gene mutations is similar than in colorectal cancer (Ari et al,
1997). The role of targeted therapy, specifically of epidermal growth
factor receptor (EGFR) inhibitors, has never been investigated in
patients with SBA. A recent report showed that a high percentage of
tumours express both EGFR and VEGF-A suggesting that these
patients could benefit from therapeutic strategies targeting EGFR and
VEGF receptors (Overman et al, 2010).
In our institution four patients with advanced SBA (three men and
one woman) were enrolled to receive cetuximab in combination with
chemotherapy. The primary site of disease was duodenum in two
patients and jejunum in the other two patients. All patients had
peritoneal carcinosis, whereas one presented also bone, abdominal
l y m p hn o d e sa n dl i v e rm e t a s t ases. Cetuximab (250mgmq
1,w i t ha
loading dose of 400mgmq
1) was associated with CPT-11-based
chemotherapy in first- (two patients) or second-line (two patients)
therapy for metastatic disease. The patients previously treated
progressed with folfiri during first-line chemotherapy. The median
number of weekly cetuximab cycles was 14 (range: 8–28). One patient
obtained a complete peritoneal response, two patients a partial
peritoneal response and one patient stable disease in all the disease
localisations. Two patients have a time to progression with cetuximab of
3 months, whereas the other two are still on cetuximab after 3 and 10
months. Two patients are still alive (overall survival of 7 and 17 months),
the other two had an overall survival of 35 and 19 months. Treatment
was well tolerated, with one patient presenting grade 3 neutropenia and
grade 3 diarrhoea. Nobody needed to have a dose modification. In three
patients KRAS status was tested, resulting in KRAS wild-type mutational
status. The same patients presented a G2 skin rash, that was associated
with the two partial responses and the complete response. Table 1 shows
the main characteristics and the results.
These case reports show that anti-EGFR therapy may have a role
in SBA, especially in those patients harbouring a wild-type KRAS
status. A prospective trial is needed to explore and to support these
preliminary observations.
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Table 1 Patients’ characteristics and results obtained with cetuximab
Total number 4
Age (years)
Median (minimum–maximum) 64.25 (57–61)
Gender, number (%)
Male 3 (75)
Female 1 (25)
Primary site (%)
Duodenum 2 (50)
Jejunum 2 (50)
Grading, number (%)
Well differentiated 0 (0)
Moderately differentiated 1 (25)
Poorly differentiated 2 (50)
KRas status
Wild-type 3 (75%)
Mutant 0 (0%)
Not available 1 (25%)
Response to cetuximab
Progression 0 (0%)
Stable disease (second line) 1 (25%)
Partial response (first and second line) 2 (50%)
Complete response (first line) 1 (25%)
Skin rash
G0 1 (25%)
G1 0 (0%)
G2 3 (75%)
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